Integrated interdisciplinary approaches to design new anti-bacterials with novel mechanisms of action to tackle antimicrobial resistance in Tuberculosis (360G-Wellcome-105342_Z_14_A)
Tuberculosis (TB) remains a serious threat to global health. The World Health Organisation estimate that 10.4 million new cases were contracted in 2015, and that over 500,000 of those cases were resistant to at least one of the antibiotics currently used to treat this condition. The spread of such resistance is a serious concern and as a result there is a need for the development of new drugs to combat TB. Recent work has identified two classes of molecule which have promising anti-tubercular properties: tetrahydroisoquinolines and non-steroidal anti-inflammatory drugs. My project will focus on the development of new anti-bacterials from these classes of molecule while exploring the reasons behind their anti-tubercular properties. This will be achieved through a combination of chemistry and molecular microbiology, making use of both laboratory and computational techniques.
Where is this data from?
This data was originally published by The Wellcome Trust. If you see something about your organisation or the funding it has received on this page that doesn't look right you can submit a grantee amendment request. You can hover over codes from standard codelists to see the user-friendly name provided by 360Giving.
Grant Details
| Amount Awarded |
0
|
| Applicant Surname | Martin |
| Approval Committee | Internal Decision Panel |
| Award Date | 2018-09-30T00:00:00+00:00 |
| Financial Year | 2017/18 |
| Grant Programme: Title | PhD Studentship (Basic) |
| Internal ID | 105342/Z/14/A |
| Lead Applicant | Mr Liam Martin |
| Partnership Value | 0 |
| Planned Dates: End Date | 2020-09-29T00:00:00+00:00 |
| Planned Dates: Start Date | 2017-10-01T00:00:00+00:00 |
| Recipient Org: Country | United Kingdom |
| Region | Greater London |